Lim Ju-hyun's bold bet pays off as Hanmi readies Eppe launch

Hanmi Pharmaceutical’s launch of Korea’s first homegrown GLP-1 obesity drug, Eppe, marks a major milestone for Vice Chair Lim Ju-hyun, who turned a once-abandoned diabetes drug candidate into the centerpiece of the company’s obesity treatment ambitions. The journey began in 2008, when Hanmi developed efpeglenatide, …

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.